As of 3:59pm ET
| +0.37 / +2.36%|
The 4 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 50.00, with a high estimate of 55.00 and a low estimate of 49.00. The median estimate represents a +211.53% increase from the last price of 16.05.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.